DLGAP1 and breast carcinoma: DLGAP1-AS2 upregulation facilitated increased ER-signaling via the inhibition of AFF3 degradation, which in turn increased cell viability, inhibited apoptosis and induced resistance to the drug tamoxifen; DLGAP1-AS2 therefore offered a promising target for anti-breast cancer therapy aimed at overcoming tamoxifen resistance [137].